Effects of telmisartan combined with atorvastatin on the expression of serum high mobility group protein,matrix metalloproteinase-9 and soluble selectin in patients with coronary heart disease and type 2 diabetes mellitus
Objective To investigate the effects of telmisartan combined with atorvastatin on the expression of serum high mobility group box B1(HMGB1),matrix metalloproteinase-9(MMP-9)and soluble selectin in patients with coronary heart disease(CHD)and type 2 diabetes mellitus(T2DM).Methods A total of 120 patients with CHD and T2DM admitted to Huzhou Zhebei Mingzhou Hospital,Huzhou from October 2019 to October 2022 were enrolled.They were divided into an observation group and a control group(60 cases in each group).Patients in both groups received atorvastatin and basic treatments.Patients in the observation group were treated with telmisartan for 8 weeks.Left ventricular ejection fraction(LVEF),glycosylated hemoglobin A1C(HbA1c),fasting blood glucose(FBG)and postprandial blood glucose(PBG),serum high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C),total cholesterol(TC)and triglyceride(TG)were measured,HMGB1,MMP-9,soluble E-selectin(sE-selectin)and sP-selectin were detected by enzyme-linked immunosorbent assay before and after treatment.Results The total effective rate of treatment was 91.67％in the observation group,significantly higher than 78.33％in the control group(P＜0.05).After treatment,HbA1c,FBG,PBG,LDL-C,TC,TG,HMGB1,MMP-9,sE-selectin,and sP-selectin were significantly lower,while HDL-C and LEVF were significantly higher in the observation group than in the control group(all P＜0.05).HbA1c,FBG,PBG,LDL-C,TC,TG,HMGB1,MMP-9,sE-selectin,and sP-selectin decreased significantly,while HDL-C and LEVF increased significantly after treatment than before in both groups(all P＜0.05).Conclusion Telmisartan combined with atorvastatin can improve clinical efficacy and reduce serum HMGB1,MMP-9 and soluble selectins in patients with CHD and T2DM.
NETL
NSTL
万方数据
